Sarepta Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.2B | $1.9B | $1.2B | $933.0M | $701.9M |
| Operating income | -$699.8M | $218.1M | -$267.8M | -$536.2M | -$459.7M |
| Cost of revenue | $25.5M | — | — | — | — |
| Cash from operations | -$205.5M | -$205.8M | -$501.0M | -$325.3M | -$443.2M |
| Capital expenditure | $102.0M | $137.0M | $76.1M | $30.8M | $38.5M |
| Free cash flow | -$307.5M | -$342.7M | -$577.1M | -$356.2M | -$481.7M |
| Share repurchases | $25.0M | $0 | $0 | — | — |
| Total assets | $3.3B | $4.0B | $3.3B | $3.1B | $3.1B |
| Total liabilities | $2.2B | $2.4B | $2.4B | $2.7B | $2.2B |
Shares outstanding 105.6M · Free float 84.7%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.